Ardent Health, Inc. (ARDT) SEC Filings & Earnings Calls
EquiReason read 12 Ardent Health, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-10-23 — CEO Martin Bonick's separation recharacterized as termination for cause due to undisclosed third-party compensation; $4.5M unpaid severance discontinued, unvested PRSUs forfeited..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 1.7B
- P/E TTM
- 22.3
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
23 Oct 20268-K · 5.02CEO Martin Bonick's separation recharacterized as termination for cause due to undisclosed third-party compensation; $4.5M unpaid severance discontinued, unvested PRSUs forfeited.open
Risks flagged
Executive misconduct risk: CEO failed to disclose third-party compensation, leading to cause termination and forfeiture of severance/equity
“Board found Bonick failed to disclose compensation from third parties; recharacterized separation as cause”
4 Sep 20268-K · 8.01Ardent Health revises non-GAAP metrics (Adjusted EBITDA down $97.7M, Adjusted EBITDAR down $97.7M) after SEC staff discussions, removing two adjustments from 2025 Form 10-K.open
Figures in the filing · each found in the filing text
| Adjusted EBITDA · FY2025 | $447M | |
| Adjusted EBITDAR · FY2025 | $612M |
Risks flagged
Non-GAAP metric revision may signal prior overstatement of profitability, raising credibility concerns
“Removal of $97.7M in adjustments after SEC staff discussions”
10 Aug 202610-QArdent Health reported Q2 2026 revenue decline and margin compression due to lower Medicaid supplemental payments and rising physician costs.earningsopen
Figures in the filing · each found in the filing text
| Net income · Q2-2026 | $35M | -64% y/y |
| Adjusted EBITDA · Q2-2026 | $115M | -32% y/y |
| Admissions · Q2-2026 | 41,104 | -1% y/y |
| Adjusted admissions · Q2-2026 | 89,326 | +2% y/y |
| Net patient service revenue per adjusted admission · Q2-2026 | $17864.00 | -4% y/y |
| Total surgeries · Q2-2026 | 31,755 | -3% y/y |
| Emergency room visits · Q2-2026 | 156,896 | +0% y/y |
| Total encounters · Q2-2026 | 1,581,207 | +6% y/y |
| Patient days · Q2-2026 | 189,223 | -3% y/y |
| Average length of stay · Q2-2026 | 4.6 | -2% y/y |
Risks flagged
Medicaid funding reduction from OBBBA
“The OBBBA may reduce the federal government's overall Medicaid expenditures and tighten Medicaid eligibility requirements.” · word for word
Rising physician costs
“The increase in professional fees as a percentage of total revenue was primarily attributable to higher costs for hospital-based providers due to rising physician-related expenses during the three months ended June 30, 2026 compared to the same prior year period.”
ACA marketplace disruption
“We also expect these reforms to ACA marketplace exchange-based plans to adversely impact results in 2026, partially offset by our ongoing resiliency and cost reduction initiatives.” · word for word
Geographic concentration in Texas and Oklahoma
“our facilities are heavily concentrated in Texas and Oklahoma, which makes us sensitive to regulatory, economic and competitive conditions and changes in those states” · word for word
4 Aug 20268-K · 2.02Ardent Health Q2 2026 revenue declined 1.4% YoY, net income fell to $17M from $73M, Adjusted EBITDA down 32.3% to $115M. Admissions -1.0%, surgeries -2.9%. Guidance reaffirmed but net income guidance lowered.earningsopen
Figures in the filing · each found in the filing text
| Total Revenue · Q2-2026 | $1.62B | -1% y/y |
| Net Income Attributable to Ardent Health · Q2-2026 | $17M | -77% y/y |
| Adjusted EBITDA · Q2-2026 | $115M | -32% y/y |
| Admissions · Q2-2026 | 41,104 | -1% y/y |
| Adjusted Admissions · Q2-2026 | 89,326 | +2% y/y |
| Total Surgeries · Q2-2026 | 31,755 | -3% y/y |
| Net Patient Service Revenue per Adjusted Admission · Q2-2026 | $17864.00 | -4% y/y |
| Operating Cash Flow · Q2-2026 | $197M | +68% y/y |
| Total Cash and Cash Equivalents · Q2-2026 | $724M | |
| Total Debt · Q2-2026 | $1.10B |
Guidance
FY26 revenue reaffirmed $6,400-$6,700M; Adjusted EBITDA reaffirmed $485-$535M; Net income lowered to $110-$163M from $129-$183M; Adjusted admissions growth 1.5%-2.5%; Capex $225-$265M
Revenue and EBITDA guidance reaffirmed but net income guidance lowered due to volume and margin pressure. Management focused on cost control and operational improvement.
Risks flagged
Volume decline in surgeries and admissions, with net income guidance lowered.
“Admissions -1.0%, surgeries -2.9% YoY; net income guidance lowered to $110-$163M from $129-$183M.”
Revenue pressure from New Mexico directed payment program timing impact.
“Revenue decline partly due to recording two quarters of New Mexico state directed payment program benefit in prior year quarter.”
30 Jun 20268-K · 5.02CEO Martin J. Bonick departed effective June 2, 2026; separation agreement filed with non-compete/non-solicit for 12 months.open
Risks flagged
CEO departure may signal strategic or performance issues; non-compete suggests potential competitive risk.
“Separation agreement includes non-competition and non-solicitation covenants for twelve months”
6 May 202610-QQ1 2026 revenue +7.0% YoY, Adjusted EBITDA +26.2% YoY, margin improvement from lower contract labor costs.earningsopen
Figures in the filing · each found in the filing text
| Net income attributable to Ardent Health, Inc. · Q1-2026 | $40M | -4% y/y |
| Adjusted EBITDA · Q1-2026 | $124M | +26% y/y |
| Adjusted admissions · Q1-2026 | 86,244 | +2% y/y |
| Net patient service revenue per adjusted admission · Q1-2026 | $18367.00 | +6% y/y |
| Salaries and benefits as % of revenue · Q1-2026 | 41.3% | |
| Contract labor as % of salaries and benefits · Q1-2026 | 2.2% | |
| Cash and cash equivalents · Q1-2026 | $610M | |
| Available liquidity · Q1-2026 | $879M | |
| Net leverage ratio · Q1-2026 | $1.00 | |
| Lease-adjusted net leverage ratio · Q1-2026 | $2.60 |
Risks flagged
Medicaid supplemental payment reduction
“We expect revenue from certain Medicaid supplemental payment programs to decline in 2026 compared to 2025 as program changes take effect.” · word for word
ACA subsidy expiration impact
“We also expect these reforms to ACA marketplace exchange-based plans to adversely impact results in 2026, partially offset by our ongoing resiliency and cost reduction initiatives.” · word for word
Operating cash flow volatility
“Cash flows used in operating activities for the three months ended March 31, 2026 totaled $60.2 million compared to $24.8 million for the same prior year period.” · word for word
5 May 20268-K · 2.02Ardent Health reported Q1 2026 revenue of $1.60B (+7.0% YoY), adjusted EBITDA of $124M (+26.3% YoY), and reaffirmed full-year 2026 guidance, with strong execution on cost management and IMPACT program.earningsopen
Figures in the filing · each found in the filing text
| Total Revenue · Q1-2026 | $1.60B | +7% y/y |
| Net Income Attributable to Ardent Health · Q1-2026 | $40M | -2% y/y |
| Adjusted EBITDA · Q1-2026 | $124M | +26% y/y |
| Adjusted Admissions · Q1-2026 | 86,244 | +2% y/y |
| Admissions · Q1-2026 | 40,932 | -1% y/y |
| Total Surgeries · Q1-2026 | 31,342 | +1% y/y |
| Net Patient Service Revenue per Adjusted Admission · Q1-2026 | $18367.00 | +6% y/y |
| Emergency Room Visits · Q1-2026 | 156,168 | -3% y/y |
Guidance
FY 2026 Total Revenue $6,400-$6,700M; Net Income $129-$183M; Adjusted EBITDA $485-$535M; Rent Expense $168M; Diluted EPS $0.90-$1.27; Adjusted Admissions Growth 1.5%-2.5%; Capital Expenditures $225-$265M
Ardent Health reaffirmed full-year 2026 guidance after strong Q1 execution, with adjusted EBITDA growth of 26% and IMPACT program on track for $55M savings.
Risks flagged
Admissions declined 1.1% YoY due to severe weather and lighter respiratory season; Exchange market dynamics remain uncertain.
“Admissions for the first quarter of 2026 decreased 1.1% year-over-year and were impacted by severe weather in certain markets and a lighter respiratory season.” · word for word
Net cash used in operating activities increased to $60M from $25M in prior year, indicating working capital pressure.
“During the first quarter of 2026, net cash used in operating activities was $60 million, compared to $25 million used in the same prior year period.” · word for word
8 Apr 2026DEF 14AProxy statement for 2026 annual meeting, disclosing executive compensation structure and 2025 performance outcomes.open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $6.30B | +6% y/y |
| Net income · FY2025 | $230M | |
| Operating cash flow · FY2025 | $471M | +49% y/y |
| Adjusted EBITDAR · FY2025 | $709M | |
| Admissions growth · FY2025 | 5.3% | |
| Adjusted admissions growth · FY2025 | 2.3% |
Risks flagged
Professional fee inflation and payor denial pressure
“The Company's Adjusted EBITDAR performance was below expectations primarily as a result of sustained professional fee inflation and increased payor denials in the second half of the year, which pressured margins despite solid volume and revenue growth.” · word for word
Ventas Master Lease financial covenant risk
“The Ventas Master Lease includes a number of significant operating and financial restrictions on us, including requirements that we maintain certain minimum portfolio coverage ratio...of at least 2.2x and guarantor fixed charge coverage ratio...of at least 1.2x and do not exceed a certain guarantor net leverage ratio of 6.75x” · word for word
16 Mar 202610-KRevenue grew 6.0% but net income fell 23.2% due to higher professional liability losses and provider assessments; OBBBA poses future Medicaid reimbursement risk.earningsopen
Figures in the filing · each found in the filing text
| Net Income · FY2025 | $230M | -23% y/y |
| Adjusted Admissions · FY2025 | 349,614 | +2% y/y |
| Net Patient Service Revenue per Adjusted Admission · FY2025 | $17748.00 | +4% y/y |
| Professional and General Liability Costs · FY2025 | $131M | +108% y/y |
| Medicaid Supplemental Payment Revenue · FY2025 | $708M | +33% y/y |
Guidance
Medicaid supplemental payment revenue expected to decline in 2026
Expects Medicaid supplemental payment revenue to decline in 2026; OBBBA may reduce Medicaid expenditures and tighten eligibility.
Risks flagged
Medicaid reimbursement reduction from OBBBA
“The OBBBA may reduce the federal government’s overall Medicaid expenditures and tighten Medicaid eligibility requirements.” · word for word
Professional liability loss escalation
“The total costs for professional and general liability losses ... were $131.3 million, $63.0 million, and $55.5 million for the years ended December 31, 2025, 2024, and 2023, respectively.” · word for word
Labor shortage and wage pressure
“The impact of labor shortages across the healthcare industry may result in other healthcare facilities, such as nursing homes, limiting admissions, which may constrain our ability to discharge patients to such facilities and further exacerbate the demand on our resources, supplies and staffing.” · word for word
4 Mar 20268-K · 2.02Ardent Health reports Q4 2025 revenue $1.61B, Adj. EBITDA $134M; FY25 revenue $6.32B (+6% Y/Y), Adj. EBITDA $545M (+9.3% Y/Y). Issues FY26 guidance: revenue $6.4-6.7B, Adj. EBITDA $485-535M. IMPACT program savings raised to $55M. Net leveraearningsopen
Figures in the filing · each found in the filing text
| Total Revenue · Q4-2025 | $1.60B | -0% y/y |
| Adjusted EBITDA · Q4-2025 | $134M | -27% y/y |
| Net Income Attributable to Ardent Health · Q4-2025 | $45M | -61% y/y |
| Adjusted Admissions · Q4-2025 | 88,583 | +2% y/y |
| Admissions · Q4-2025 | 40,896 | +1% y/y |
| Operating Cash Flow · Q4-2025 | $223M | +86% y/y |
| Net patient service revenue per adjusted admission · Q4-2025 | $17757.00 | -2% y/y |
| Total Revenue (FY) · FY2025 | $6.32B | +6% y/y |
| Adjusted EBITDA (FY) · FY2025 | $545M | +9% y/y |
| Operating Cash Flow (FY) · FY2025 | $471M | +49% y/y |
Guidance
FY26 revenue $6,400-6,700M; FY26 Adj. EBITDA $485-535M; FY26 net income $221-280M; FY26 capex not explicitly guided but implied by D&A $170-175M
FY26 revenue guidance implies ~3-6% growth; Adj. EBITDA guidance below FY25 actual of $545M, reflecting headwinds. Management expects return to growth in 2027.
Risks flagged
Payor denial and professional fee pressures continue to impact revenue per admission.
“mitigate the payor denial and professional fee industry pressures we outlined on the third quarter earnings call” · word for word
Expiration of enhanced Exchange subsidies expected to create headwind in 2026.
“stepping over annualization of the aforementioned industry headwinds and the expiration of enhanced Exchange subsidies” · word for word
Q4 Adj. EBITDA decline of 26.6% Y/Y due to New Mexico directed payment program comparison.
“Adjusted EBITDA decreased 26.6% year-over-year to $134 million” · word for word
14 Nov 202510-QQ3 2025 revenue grew 8.8% YoY, but net income swung to a loss due to a $42.6M accounting change and $47.2M liability accrual. Adjusted EBITDA rose 46% YoY.earningsopen
Figures in the filing · each found in the filing text
| Total revenue · Q3-2025 | $1.58B | +9% y/y |
| Net income attributable to Ardent Health, Inc. · Q3-2025 | $-23M | |
| Adjusted EBITDA · Q3-2025 | $143M | +46% y/y |
| Admissions · Q3-2025 | 41,862 | +6% y/y |
| Adjusted admissions · Q3-2025 | 89,328 | +3% y/y |
| Net patient service revenue per adjusted admission · Q3-2025 | $17252.00 | +6% y/y |
| Cash and cash equivalents · Q3-2025 | $609M | |
| Available liquidity · Q3-2025 | $904M |
Risks flagged
Medicaid reimbursement reduction risk
“The OBBBA may reduce the federal government’s overall Medicaid expenditures and tighten Medicaid eligibility requirements.” · word for word
Professional liability litigation risk
“During the three and nine months ended September 30, 2025, we recorded an increase in our professional liability reserves of $47.2 million.” · word for word
Revenue accounting estimate risk
“a change in accounting estimate resulting from a modification to the technique used to estimate the collectability of accounts receivable... resulted in a decrease in revenue of $42.6 million.” · word for word
Concentration risk in Texas and Oklahoma
“our facilities are heavily concentrated in Texas and Oklahoma, which makes us sensitive to regulatory, economic and competitive conditions and changes in those states.” · word for word
12 Nov 20258-K · 2.02Ardent Health reported Q3 2025 earnings with revenue growth but net loss; revised FY2025 adjusted EBITDA guidance down to $530-555M from $575-615M due to professional fee expense growth and payor denials.earningsopen
Figures in the filing · each found in the filing text
| Total Revenue · Q3-2025 | $1.58B | +9% y/y |
| Net Loss Attributable to Ardent Health · Q3-2025 | $-23M | -188% y/y |
| Adjusted EBITDA · Q3-2025 | $143M | +46% y/y |
| Adjusted Admissions · Q3-2025 | 89,328 | +3% y/y |
| Admissions · Q3-2025 | 41,862 | +6% y/y |
| Net Patient Service Revenue per Adjusted Admission · Q3-2025 | $17252.00 | +6% y/y |
| Operating Cash Flow · Q3-2025 | $154M | +71% y/y |
Guidance
FY2025 adjusted EBITDA guidance revised to $530-555M from $575-615M; revenue guidance reaffirmed at $6,200-6,450M; net income guidance cut to $121-146M from $245-285M; EPS guidance cut to $0.85-1.03 from $1.73-2.01; capex unchanged at $215-235M; adjusted admissions growth unchanged at 2-3%; net patient service revenue per adjusted admission growth unchanged at 2.1-4.4%
Guidance cut reflects higher professional fee expenses and payor denials; demand trends remain strong but cost pressures persist.
Risks flagged
Professional fee expense growth accelerating to 11% in Q3, above expectations.
“Professional Fee growth accelerated to 11% in the third quarter.” · word for word
Payor denials more pronounced in Q3, impacting revenue and earnings.
“Payor denials were more pronounced in the third quarter.” · word for word
Professional liability reserve increase of $54 million due to adverse claim developments in New Mexico.
“Increase in reserves included an adjustment of $54 million attributable to the emergence of adverse prior period claim developments.” · word for word
Ardent Health, Inc. — questions
- What did Ardent Health, Inc. file recently?
- 12 SEC filings in the last 12 months. Latest: 8-K on 2026-10-23 — CEO Martin Bonick's separation recharacterized as termination for cause due to undisclosed third-party compensation; $4.5M unpaid severance discontinued, unvested PRSUs forfeited.
Every figure on this page comes from Ardent Health, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.